VRC 607/ACTG A5378: A Phase 1, Single Dose Study of the Safety and Virologic Effect of an HIV-1 Specific Broadly Neutralizing Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS) or VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously to HIV-Infected Adults
Antibodies against HIV
Sponsor: NIH
Enrolling: Male and Female Patients
Study Length: 1 Years
Clinic Visits: 23
IRB Number: AAAR9464
U.S. Govt. ID: NCT02840474
Contact: Jolene Noel-Connor: 212-305-6795 / jn246@cumc.columbia.edu
Additional Study Information: We are testing two antibodies directed against HIV virus. The human body uses antibodies as one way to help fight infection.The antibodies are called VRC01LS and VRC07-523LS and they are given by IV infusion. Each participant will receive one dose by infusion. The main purpose of this study is to see if these two antibodies are safe and how a participants body will respond to them. The monoclonal antibody used in the study targets the specific HIV-1 binding site which the virus uses to attach to cells of the immune system. We will measure the amount of the antibody in your body and how much stays in your body over time. We will also check to see if your CD4+ or HIV viral load levels change during the study.We are looking for adults ages 18 to 70 who are HIV infected but otherwise healthy and who have not yet started anti-HIV therapy. You will be compensated for your time and travel.
This study is closed
Magdalena Sobieszczyk, MD
Do You Qualify?
Are you HIV positive? Yes No
Are taking HIV medications? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Jolene Noel-Connor